Galderma, Ipsen sales and marketing update

Ipsen and Galderma renewed and amended a 2007 deal to commercialize Ipsen's Dysport abobotulinumtoxinA for aesthetic and dermatological use. Galderma will continue to commercialize the product in Brazil and Argentina and will now also exclusively commercialize the product in Australia. Discussions regarding Paraguay, which was included in the original 2007 deal, are ongoing. Ipsen declined to provide details, while Galderma could not be reached for comment (see BioCentury, Dec. 10, 2007). ...